A Disease-Agnostic Custom Discovery-to-Targeted Proteomics Solution for Drug Discovery & Development
Researchers need to understand real-time biology and how different disease states and treatment conditions impact a patient’s proteome.
Despite the impact of genomics and transcriptomics in revolutionizing healthcare and research, these technologies might not always provide robust predictions on which individuals will respond effectively to a given therapy.
InoKey™ solves this problem by providing researchers with a single solution to identify novel protein biomarkers and translating those findings into a functional assay with clinical utility.
An end-to-end discovery to targeted proteomics solution supporting you every step of the way — from experimental design to data acquisition, interpretation, reporting, and clinical utility.
Global, broad-scale proteomics analyses to identify and quantify novel biomarkers, therapeutic targets, regulatory mechanisms, and molecular pathways:
Our in-house bioinformatics team supports you every step of the way, building bespoke workflows to simplify your complex omics data and guide your decisions. With expertise in the latest tools and data analysis methods and utilizing additional data sources to transform discovery proteomics findings into robust, targeted assays, we help you measure key proteins and streamline your drug development goals.
(In accordance with FDA guidelines for bioanalytical method development)
Quantitative and selective tracking of predefined protein targets within a complex biological sample in a hypothesis-driven approach
A separate IP-MS option is also available for the absolute quantification of one or multiple protein biomarkers in the pg/ml range.
Please fill out this form to access the FibroKey™ On Demand Webinar
Please fill out this form to access the NeuroKey-3™ On Demand Webinar
Don’t miss out on this limited-time opportunity to gain a competitive edge and achieve groundbreaking discoveries. Please fill out this form to access the MasterKey™ catalog.
Please fill out the form to subscribe to our newsletter.